FDA
-
-
-
-
-
-
-
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid C
-
-
-
-
-
-
-
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Announces IVDR Certification for clonoSEQ in European Union
-
-
-
-
-
-
-
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Announces Collaboration with Takeda (TAK) to Measure Minimal Residual Disease with clonoSEQ Assay
-
-
-
-
-
-
-
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
-
-
-
-
-
-
-
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
-
322,198 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

